Your session is about to expire
← Back to Search
Retinoic Acid Receptor Agonist
Palovarotene for Stone Man Syndrome (MOVE Trial)
Phase 3
Waitlist Available
Research Sponsored by Clementia Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Abstinent or using two highly effective forms of birth control.
Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening, every 6 months up to 4 years
Awards & highlights
MOVE Trial Summary
This trial is for a drug to treat Fibrodysplasia Ossificans Progressiva, which is a rare disease that causes bones to form in muscles and connective tissue, leading to loss of movement and disability.
Eligible Conditions
- Stone Man Syndrome
MOVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMOVE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ screening, every 6 months up to 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening, every 6 months up to 4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Annualized New Heterotopic Ossification (HO)
Secondary outcome measures
Number of Body Regions With New HO
Percentage of Participants With Any New HO
Percentage of Participants With Flare-Ups
+1 moreOther outcome measures
FOP-Physical Function Questionnaire
PROMIS Global Health Scale
Range of Motion
Side effects data
From 2022 Phase 3 trial • 107 Patients • NCT0331263446%
Dry skin
32%
Drug eruption
26%
Alopecia
21%
Lip Dry
20%
Erythema
19%
Arthralgia
17%
Pruritus
14%
Pruritus generalised
14%
Pruritus generalized
14%
Rash
14%
Skin exfoliation
14%
Dry Eye
12%
Chapped Lips
12%
Paronychia
12%
Epiphyses Premature Fusion
11%
Nasopharyngitis
11%
Skin Abrasion
11%
Pain In Extremity
10%
Cheilitis
9%
Dermatitis
9%
Fall
9%
Headache
7%
Peripheral swelling
7%
Ear Infection
7%
Upper Respiratory Tract Infection
7%
Neck Pain
7%
Contusion
6%
Bone density decreased
6%
Decreased Appetite
6%
Alanine aminotransferase increased
6%
Skin irritation
6%
Rash maculo-papular
6%
Vomiting
6%
Musculoskeletal Pain
6%
Cough
6%
Bronchitis
5%
Influenza
5%
Ingrowing nail
5%
Rash generalized
4%
Decubitus Ulcer
4%
Joint range of motion decreased
4%
Condition Aggravated
4%
Otitis Media
4%
Abdominal Pain
4%
Back Pain
4%
Epistaxis
4%
Hypoacusis
4%
Pain In Jaw
4%
Peripheral Swelling
4%
Nausea
4%
Groin Pain
4%
Fatigue
3%
Ocular Hyperemia
3%
Rash Pruritic
3%
Oropharyngeal Pain
3%
Nasal Dryness
3%
Alanine Aminotransferase Increased
3%
Gamma-Glutamyltransferase Increased
3%
Abnormal Dreams
3%
Depressed Mood
3%
Eczema
2%
Corona virus infection
2%
Pain in jaw
2%
Myalgia
2%
Diarrhea
2%
Gastroenteritis
1%
Ear pain
1%
Ear Pain
1%
Cellulitis
1%
Escherichia Sepsis
1%
Mycoplasma Infection
1%
Urosepsis
1%
Malnutrition
1%
Anemia
1%
Pharyngitis
1%
Skin Disorder
1%
Skin Plaque
1%
Swelling Face
1%
Back Injury
1%
Extraskeletal Ossification
1%
Musculoskeletal Stiffness
1%
Dizziness
1%
Ear Discomfort
1%
Non-Cardiac Chest Pain
1%
Pain
1%
Blood Alkaline Phosphatase Increased
1%
Insomnia
1%
Mobility Decreased
1%
Pneumonia
1%
Urinary Tract Infection
1%
Traumatic Fracture
1%
Abnormal Loss Of Weight
100%
80%
60%
40%
20%
0%
Study treatment Arm
Palovarotene 20/10 mg
Untreated (PVO-1A-001)
Flare-Up Treatment: Supplemental SS
Untreated (PVO-1A-001)
Palovarotene 5 mg
MOVE Trial Design
1Treatment groups
Experimental Treatment
Group I: Palovarotene Chronic/Flare-Up RegimenExperimental Treatment1 Intervention
Participants received 5 mg palovarotene once daily for up to 48 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Palovarotene
2014
Completed Phase 3
~260
Find a Location
Who is running the clinical trial?
Clementia Pharmaceuticals Inc.Lead Sponsor
10 Previous Clinical Trials
628 Total Patients Enrolled
Ipsen Medical DirectorStudy DirectorIpsen
251 Previous Clinical Trials
54,309 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger